Immunomedics advances two therapeutic programs toward clinical trials; Data presented on promising new products for treatment of solid tumors and non-Hodgkin's Lymphoma.MINNEAPOLIS--(HealthWire)--June 14, 1995--Immunomedics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :IMMU IMMU Independent Munitions Maintenance Unit ) today announced that its humanized monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing product, hMN-14, has demonstrated encouraging results in a pilot clinical trial involving 17 patients and in preclinical studies for the treatment of several cancers, including colorectal and ovarian cancer. Data presented at the Society of Nuclear Medicine annual meeting show hMN-14 demonstrates the same excellent tumor targeting, as compared with the murine murine /mu·rine/ (mur´en) pertaining to, derived from, or characteristic of mice or rats. mu·rine adj. form of MN-14. "In addition to the encouraging targeting results achieved with our humanized MN-14 antibody, we are very pleased to have observed in these studies no human anti-mouse antibody (HAMA) response in any patient," said Dr. David M. Goldenberg, Chairman of Immunomedics. "Based on these results, we plan to initiate an expanded study of hMN-14 for radioimmunotherapy of carcinoembryonic antigen-producing, or CEA CEA carcinoembryonic antigen. CEA abbr. carcinoembryonic antigen CEA (Carcinoembryonic antigen) , cancers, such as colorectal and ovarian cancers." Immunomedics also presented data supporting the advantage of using yttrium yttrium (ĭt`rēəm) [for Ytterby, a town in Sweden], metallic chemical element; symbol Y; at. no. 39; at. wt. 88.9059; m.p. about 1,522°C;; b.p. 3,338°C;; sp. gr. about 4.45; valence +3. Yttrium is a highly crystalline iron-gray metal. radioisotope radioisotope: see radioactive isotope. Radioisotope (biology) A radioactive isotope used in studying living systems, such as in the investigation of metabolic processes. over iodine in conjunction with its humanized LL2 monoclonal antibody for the treatment of non-Hodgkin's lymphoma. According to the studies, use of yttrium results in enhanced retention of the radioisotope at the cancer site as compared to iodine, which is rapidly metabolized, thereby providing a potentially stronger therapeutic effect. Based on these results, the company plans to advance its humanized LL2 antibody into clinical studies, subject to regulatory approval. Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infectious or other diseases. The company's colorectal cancer imaging agent, CEA-Scan(TM), is under review for marketing approval by the U.S, Food and Drug Administration, as well as by regulatory agencies in Europe and Canada. In addition, Immunomedics currently has a therapeutic product and several other diagnostic imaging products in clinical trials. CONTACT: Immunomedics, Inc., Morris Plains, N.J. Amy Factor, 201/605-8200 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion